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ABSTRACT
Introduction: Optimal ventilator management for
patients with acute respiratory distress syndrome
(ARDS) remains uncertain. Lower tidal volume
ventilation appears to be beneficial, but optimal
management of positive end-expiratory pressure
(PEEP) remains unclear. The Esophageal Pressure-
Guided Ventilation 2 Trial (EPVent2) aims to examine
the impact of mechanical ventilation directed at
maintaining a positive transpulmonary pressure (PTP)
in patients with moderate-to-severe ARDS.
Methods and analysis: EPVent2 is a multicentre,
prospective, randomised, phase II clinical trial testing
the hypothesis that the use of a PTP-guided ventilation
strategy will lead to improvement in composite
outcomes of mortality and time off the ventilator at
28 days as compared with a high-PEEP control. This
study will enrol 200 study participants from 11
hospitals across North America. The trial will utilise a
primary composite end point that incorporates death
and days off the ventilator at 28 days to test the
primary hypothesis that adjusting ventilator pressure to
achieve positive PTP values will result in improved
mortality and ventilator-free days.
Ethics and dissemination: Safety oversight will be
under the direction of an independent Data and Safety
Monitoring Board (DSMB). Approval of the protocol was
obtained from the DSMB prior to enrolling the first study
participant. Approvals of the protocol as well as informed
consent documents were also obtained from the
Institutional Review Board of each participating institution
prior to enrolling study participants at each respective
site. The findings of this investigation, as well as
associated ancillary studies, will be disseminated in the
form of oral and abstract presentations at major national
and international medical specialty meetings. The
primary objective and other significant findings will also
be presented in manuscript form. All final, published
manuscripts resulting from this protocol will be
submitted to PubMed Central in accordance with the
National Institute of Health Public Access Policy.
Trial registration number: ClinicalTrials.gov under
number NCT01681225.
INTRODUCTION
Optimal ventilator management for patients
with acute respiratory distress syndrome
(ARDS) remains uncertain. Lower tidal
volume ventilation appears to be beneﬁcial,
1
but optimal management of positive
end-expiratory pressure (PEEP) remains
unclear. Higher levels of PEEP have been
shown to be protective in numerous animal
experiments but have only shown equivocal
beneﬁt in human clinical trials.
2 Recently,
however, an individual patient meta-analysis
combining data from these trials suggested
that higher PEEP, when added to use of
lower tidal volumes, results in an adjusted
risk ratio of 0.90 (95% CI 0.81 to 1.00;
p=0.049) in patients with moderate-to-severe
ARDS.
3 Thus, incremental improvements
offer the potential for additional mortality
reduction, and the central question remains
how best to optimise PEEP for an individual
patient.
Lung inﬂation reﬂects transpulmonary
pressure (PTP), the difference between pres-
sures at the airway opening and the pleural
space (PTP=airway pressure−pleural pres-
sure). Clinicians routinely manage mechan-
ical ventilation by controlling pressures
measured at the airway. This would be a satis-
factory strategy if pleural pressure values
were predictable or restricted to a narrow
range. However, there is evidence that
pleural pressure varies widely and unpredict-
ably among patients with ARDS, likely due to
factors such as obesity, abdominal ﬂuid accu-
mulation and oedema, which inﬂuence the
mechanical behaviour of the chest wall and
diaphragm.
4 This wide range of pleural pres-
sure among individuals could signiﬁcantly
affect lung inﬂation produced by mechanical
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of 18 cm H2O could be too low in a patient with a
pleural pressure of 20 cm H2O, allowing collapse of
some airspaces with each expiration and leading to
atelectrauma,
5 or too high in a patient with a pleural
pressure of 5 cm H2O, causing haemodynamic com-
promise, increased dead space ventilation and overdis-
tension of the lungs at end-inﬂation. It is possible that
the inconsistency in the results of clinical trials of
PEEP
67reﬂects a failure to individualise ventilator set-
tings for pleural pressure in each patient.
8
In a single centre, phase I randomised controlled trial,
mechanical ventilation directed by esophageal pressure
was compared with ventilation using the ARDSNet proto-
col. In this study, nearly all patients who were managed
using the esophageal pressure measurements required
adjustment upwards of their set PEEP level to maintain
a transpulmonary pressure of greater than zero. The
ratio of blood oxygen tension to inspired oxygen frac-
tion (PaO2, partial pressure of oxygen dissolved in arter-
ial blood/FiO2, fraction of inspired oxygen; PaO2/FiO2)
at 72 h was higher in the intervention (EPVent) group
than controls, and respiratory system compliance was sig-
niﬁcantly improved. This trial showed a trend towards
reduced mortality that was maintained at 6 months.
9
To further explore the use of PTP values to guide venti-
lation in patients with ARDS, our group, with the
support of the National Heart, Lung and Blood Institute
(NHLBI), has designed the EPVent2 study, a rando-
mised clinical trial that aims to examine the impact of
mechanical ventilation directed at maintaining a positive
PTP in patients with moderate-to-severe ARDS. This
paper describes the study procedures and planned ana-
lyses for this clinical trial. The trial is registered on
ClinicalTrials.gov under number NCT01681225.
METHODS AND ANALYSIS
Administrative structure
This study is under the auspices of the NHLBI (Grant
Number U01-HL108724). The Medical Coordinating
Center (MCC) at Beth Israel Deaconess Medical Center
(BIDMC) is responsible for study conduct, safety moni-
toring, personnel training, data management and ran-
domisation. The Physiology Core Laboratory (PCL), also
at BIDMC, analyses waveforms collected on each patient
and provides specialised equipment and software train-
ing to study centres. The biospecimen repository at the
Harvard School of Public Health in Boston,
Massachusetts, USA, is responsible for performing
primary analyses on all specimens, as well as storing
remaining specimens from patients who have given sep-
arate consent in a biorepository. The EPVent2 Steering
Committee consists of the head of the MCC and the
PCL, a scientiﬁc advisor and the principal investigator
(PI) from each recruiting centre. This committee collab-
oratively oversees all aspects of the study design and the
protocol implementation (ﬁgure 1).
Study design
To test the hypothesis that adjusting ventilator pressure
to achieve positive PTP values will lead to improvement
in composite outcomes of mortality and time off the
ventilator at 28 days, the EPVent2 group has designed a
multicentre, prospective, randomised, phase II clinical
trial. Overall study ﬂow is presented in ﬁgure 2.
Development of the EPVent2 trial protocol
There are several key differences between the EPVent1
trial and the EPVent2 trial. In the current trial, we limit
enrolment to patients with moderate or severe ARDS
(P/F of 200 or below). We also have changed the
control group protocol to a higher PEEP approach. The
duration of our intervention has been extended from 3
to 28 days for the EPVent2 trial. Finally, our primary end
point for the current trial is a novel composite measure
that combines ventilator-free days and mortality at
28 days, whereas in the EPVent1 trial with fewer partici-
pants we studied the improvement in oxygenation at
72 h. Table 1 summarises the main differences between
the two protocols.
Restriction of enrolled patients to moderate-to-severe ARDS
In this trial we elected to restrict enrolment to patients
with moderate-to-severe ARDS with P/F <200. This deci-
sion was primarily based on a meta-analysis published by
Briel et al,
3 which showed higher levels of PEEP to be
associated with increased survival among the subset of
patients with what is now deﬁned as moderate-to-severe
ARDS (P/F <200). Given that the PTP-guided strategy
typically leads to ventilation using higher levels of PEEP,
we felt limitation to patients with moderate-to-severe
ARDS to be both clinically and scientiﬁcally appropriate.
Additionally, this restriction may enhance the difference
between the EPVent group and the control group
insofar as sicker patients stand to gain the most from
individualised treatment.
Figure 1 Administrative structure (NHLBI, National Heart,
Lung and Blood Institute; DSMB, Data and Safety Monitoring
Board).
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In this trial we opted to use a high-PEEP control arm as
opposed to the ARDSNet ventilation guidelines used in
our pilot study. The rationale for this modiﬁcation is
based on three key points. First, given our enrolment
restriction to patients with moderate-to-severe ARDS, we
did not feel comfortable utilising a low-PEEP strategy for
the control arm based on the ﬁndings by Briel et al
3 dis-
cussed previously. Additionally, our phase I study had
already shown beneﬁto faP TP-guided strategy over a
low-PEEP strategy.
9 Finally, we wanted to ensure that the
appropriate comparison was being made between venti-
lation strategies to determine whether empirically raising
PEEP (through a high-PEEP control arm) will result in
the same outcomes as those achieved using a PTP-guided
ventilation strategy. We therefore adopted a high-PEEP
algorithm previously used in the OSCILLATE trial for
the control group arm.
10
Figure 2 Overview of study
design (ARDS, acute respiratory
distress syndrome; EPVent,
Esophageal Pressure-Guided
Ventilation).
Table 1 Comparison of EPVent1 phase 1 and EPVent2
phase 2 trials
Factor EPVent1 EPVent2
Number of
participants
61 actual 200 planned
Number of
centres
1 11 planned
Control group
strategy
ARDSNet
study (low tidal
volume)
OSCILLATE study
control group
(high-PEEP)
Funding Institutional NIH/NHLBI
ARDS
severity
P/F <300 P/F <200
Outcomes PaO2:FiO2 at
72 h
Composite measure of
mortality and
ventilator-free days at
28 days
Duration of
intervention
3 days 28 days
Additional
studies
Biomarker
analysis
Biomarker analysis
Echocardiography
CT
ARDS, acute respiratory distress syndrome; EPVent, Esophageal
Pressure-Guided Ventilation; FiO2, fraction of inspired oxygen;
NHLBI, National Heart, Lung and Blood Institute; NIH, National
Institutes of Health; PaO2, partial pressure of oxygen dissolved in
arterial blood; PEEP, positive end-expiratory pressure.
Box 1 Esophageal Pressure-Guided Ventilation 2
(EPVent2) study exclusion criteria
▸ Received mechanical ventilation more than 96 h.
▸ Recently treated for bleeding varices, stricture, haematemesis,
esophageal trauma, recent esophageal surgery or other contra-
indication for nasogastric tube placement.
▸ Severe coagulopathy (platelet count <5000/μL or international
normalised ratio >4).
▸ History of lung or liver transplantation.
▸ Elevated intracranial pressure or conditions where
hypercapnia-induced elevations in intracranial pressure should
be avoided (including intracranial bleeding, cerebral contusion,
cerebral oedema, mass effect (midline shift on CT scan), flat
EEG for ≥2 h).
▸ Evidence of active air leak from the lung (including broncho-
pleural fistula, pneumothorax, pneumomediastinum or air leak
from existing chest tube).
▸ Participation in other intervention trials for acute respiratory
distress syndrome, or sepsis within the past 30 days.
▸ Neuromuscular disease that impairs ability to ventilate spon-
taneously (including C5 or higher spinal cord injury, amyo-
trophic lateral sclerosis, Guillain-Barre syndrome or
myasthenia gravis).
▸ Severe chronic liver disease (Child-Pugh Score ≥12).
▸ Patients not committed to full support.
▸ Treating clinician refusal, or unwillingness to commit to con-
trolled ventilation for at least 24 h.
▸ Inability to get informed consent from the patient or
surrogate.
▸ Use of rescue therapies prior to enrolment (including nitric
oxide, ECMO, prone positioning or high frequency oscillation),
unless therapies were used as the initial mode of ventilation.
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Adult patients aged 16 years and older, admitted to the
intensive care unit (ICU) with moderate-to-severe ARDS,
will be enrolled. The Berlin Conference deﬁnition will be
used to identify patients with moderate-to-severe ARDS,
including (A) hypoxaemic respiratory failure with PaO2/
FiO2 ratio <200 mm Hg, (B) bilateral alveolar inﬁltrates
on chest X-ray not present for more than 7 days, (C)
respiratory failure not fully explained by cardiac failure
or ﬂuid overload and (D) intubation on controlled venti-
lation and receiving PEEP ≥5c mH 2O. Patients with dur-
ation of ARDS ≥36 h or duration of mechanical
ventilation ≥96 h will be excluded. A full list of exclusion
criteria can be seen in box 1.
Patients will be recruited from approximately 11 clinical
sites in North America with experience in the identiﬁca-
tion and management of ARDS. A full list of the participat-
ing institutions is displayed in box 2. The resulting study
population is expected to be representative of the North
American adult acute care hospital population.
Study coordinators at each site will visit the ICUs daily
to identify potential candidates for enrolment.
Screening logs will be maintained at each site and
tracked using an electronic screening tool (Studymaker.
com). Once a patient is deemed eligible for the study,
the designated substitute decision maker will be
approached by a study investigator to give informed
consent. Eligible patients will be enrolled, randomised
and initial ventilator adjustments made within 36 h of
the time the last ARDS criterion was met.
Randomisation and blinding
After enrolment, patients will be randomised to either
the EPVent group or the control group using a block
randomisation scheme at a 1:1 ratio. Randomisation will
be stratiﬁed by enrolment site. Assignment schedules
will be generated for each clinical site, and each patient
will be assigned using a web-based system (Studymaker.
com) managed by the MCC.
All patients must be enrolled, randomised and initial
ventilator adjustments made within 36 h of the time the
last inclusion criterion was met. The last inclusion criter-
ion may be met at either the network hospital or a refer-
ring hospital.
Investigators will remain blinded to the results of the
study until study completion. The patient safety monitor,
unblinded statistician and Data and Safety Monitoring
Board (DSMB) will have full access to unblinded data
throughout the study.
Interventions
Ventilation strategy
Following randomisation to either the intervention
(EPVent) or the control group, esophageal balloon
catheters will be placed in all patients. The following
variables will then be measured prior to initiation of
study ventilation: airway pressure, ﬂow, esophageal pres-
sure, PTP and expired partial pressure of carbon dioxide
to allow calculation of dead space.
Once adequately sedated, all participants will have an
initial alveolar recruitment manoeuvre for 30 s at
35 cm H2O to standardise the lung volume history. The
ventilation mode will be set to either pressure control or
volume control ventilation. Tidal volume (Vt) will be set
to 6 mL/kg and monitored to remain within a working
range of 4–6 mL/kg. Target PaO2 will be 55–80 mm Hg,
and target pulse oximeter saturation (SpO2)8 8 –93%.
EPVent group
For patients randomised to the EPVent group, the overall
goal is to employ an open-lung strategy that includes low
tidal volumes and maintenance of a positive PTP at
end-expiration. After measuring the PTP during an expira-
tory hold (Ptpexp), the PEEP and FiO2 will be adjusted to
achieve a Ptpexp and FiO2 combination shown in one of
the columns of table 2. Ventilator adjustments will then be
made as required by blood gas values or oxygen saturation
by moving right or left, one table column at a time.
Once a patient has reached step 2 or 3 of table 2 and
has been on the EPVent protocol for at least 48 h, they
may be transitioned to the conventional PEEP/FiO2
table and begin weaning (table 3).
Control group
For patients randomised to the control group, the
overall goal is to also employ an open-lung strategy using
low tidal volumes and an alternative high-PEEP strategy.
The initial ventilator settings will be chosen from the
control grid, shown in table 4 before measuring the
esophageal pressure.
Choosing the settings from the table prior to measur-
ing esophageal pressure will help reduce possible inﬂu-
ence of knowledge of pressure measurements on the
control patient’s ventilator settings. The control group
PEEP and FiO2 will be managed without reference to
the esophageal pressure measurements, moving right or
left on the table as required by blood gas values or
Box 2 Esophageal Pressure-Guided Ventilation 2
(EPVent2) study participating centres
▸ Beth Israel Deaconess Medical Center, Boston, Massachusetts,
USA.
▸ Laval University, Quebec City, Quebec, Canada.
▸ Massachusetts General Hospital, Boston, Massachusetts, USA.
▸ Montefiore Medical Center, Bronx, New York, USA.
▸ Orlando Health Systems, Orlando, Florida, USA.
▸ St. Joseph’s Hospital, Hamilton, Ontario, Canada.
▸ Toronto General Hospital, Toronto, Ontario, Canada.
▸ University of Cincinnati, Cincinnati, Ohio, USA.
▸ University of Massachusetts Memorial Medical Center,
Worcester, Massachusetts, USA.
▸ University of Michigan, Ann Arbor, Massachusetts, USA.
▸ Vancouver General Hospital, Vancouver, British Columbia,
Canada.
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Open Accessoxygen saturation. Goal plateau pressure in the control
group is ≤35 cm H2O. If plateau pressure exceeds
35 cm H2O, tidal volume will be decreased to 5 or
4 mL/kg PBW as necessary.
Protocol ventilation will be followed in both groups until
the patient is capable of unassisted breathing for a period
of 48 h, dies, is discharged or otherwise withdrawn from
the study, for a maximum of 28 days. Weaning may be
initiated after the following criteria are met: (A)
FiO2≤0.40, (B) PEEP≤10 cm H2O, (C) systolic arterial
blood pressure is ≥80 mm Hg without escalating vasopres-
sor requirements or haemodynamic instability and (D) the
patient is able to make breathing efforts to trigger the ven-
tilator for pressure support ventilation. Weaning proce-
dures will be common to both groups and protocol driven.
Patients will be considered to have completed the
study ventilator procedures if any of the following condi-
tions occur: (A) death, (B) hospital discharge, (C)
patient or proxy withdraws consent, (D) clinician or
researcher determines that the trial is no longer in the
patient’s best interest or (E) completion of a period of
48 h of unassisted breathing. Any additional require-
ments after this point for positive pressure ventilation
will be addressed by the team caring for the patient.
Co-interventions
Patients in both groups will be managed according to
existing care protocols at the study sites. These include
sedation, glucose control, sepsis management and infec-
tion control protocols. These existing protocols at each
site have been reviewed by the PIs and found to be in
line with current practice.
Blood sampling
Blood samples will be obtained at baseline (after ran-
domisation and before initiation of study intervention)
on day 3 of study and on day 7 of study. Sample biomar-
kers of interest are listed in table 5. Patients will have the
option of consenting to have their blood stored in a
biorepository for future investigations, including genetic
testing. For patients who grant speciﬁc consent, any
blood left over after biomarker analyses will be stored
indeﬁnitely in the biorepository at the Harvard School
of Public Health.
Echocardiography
At select centres, a complete transesophageal echocar-
diogram will be performed on patients in both groups at
the following time points: (1) prior to initiation of study
procedures and (2) 24 h after enrolment. These exami-
nations will be performed only at participating sites.
Data collection
Baseline demographics and clinical characteristics such
as age, sex, race, comorbidities, ARDS risk factors,
Sequential Organ Failure Assessment (SOFA) score, con-
comitant medications (eg, aspirin, steroids, statin) and
co-interventions (eg, prone positioning, nitric oxide
therapy, continuous renal replacement therapy) will be
recorded. Additional variables collected throughout
study enrolment will include vital signs and laboratory
values obtained during the course of routine clinical
care, sedative and paralytic administration, vasopressor
requirements, use of rescue therapies and chest tube
placement. The investigation will utilise the REDCap
system for data management and storage. This secure,
web-based system provides robust data validation rou-
tines, custom reporting and straightforward integration
with statistical software packages such as Statistical
Analysis Software (SAS).
Outcomes
Clinical outcomes
The trial will utilise a primary composite end point that
incorporates death and days off the ventilator at 28 days
in such a manner that death constitutes a more serious
outcome. Every participant in the treatment group is
compared with every participant in the control group
and assigned one number resulting from each compari-
son as shown in table 6. As mortality outcome is clinic-
ally more important, death takes precedence over days
off the ventilator. These scores are summed to obtain a
cumulative score for each participant. The cumulative
scores are then tallied for each treatment group to form
a test statistic by the Mann-Whitney technique.
Secondary clinical outcome assessments will include
requirement for rescue therapies, length of mechanical
Table 2 Oxygenation management table—EPVent group
Step 1234567891 0 1 1 1 2 1 3
FiO2 0.3 0.4 0.5 0.5 0.6 0.6 0.7 0.7 0.8 0.8 0.9 0.9 1.0
Ptpexp 0002233445566
EPVent, Esophageal Pressure-Guided Ventilation; FiO2, fraction of inspired oxygen; Ptpexp, end-expiratory transpulmonary pressure.
Table 3 Transitioning EPVent group to control settings
for weaning
Step 1 2 3 3 5 6
FiO2 0.3 0.3 0.3 0.4 0.4 0.4 Return
patient to the
EPVent
protocol
settings
PEEP 5 8 10 10 12 14
EPVent, Esophageal Pressure-Guided Ventilation; FiO2, fraction of
inspired oxygen; PEEP, positive end-expiratory pressure.
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Hospital survivors will undergo a brief follow-up phone
survey to assess survival, functional status (Barthel
Index), health-related quality of life (SF-12) and frailty
(VES-13) at 12 months after enrolment.
Mechanistic outcomes
Secondary analyses will include evaluations of the clin-
ical efﬁcacy of adjusting ventilator pressure to achieve
appropriate Ptp values as predicted by identiﬁable fea-
tures of respiratory mechanics. Speciﬁcally, the study will
examine correlations among esophageal pressure,
gastric pressure and bladder pressure, as well as the cor-
relation between esophageal pressure and plateau pres-
sure, a known predictor of mortality in ARDS. In
addition, the study will examine the relationship
between PTP-guided ventilation and the levels of biomar-
kers previously associated with ventilator-induced lung
injury and with poor outcomes in ALI (table 5).
Sample size estimation
To adequately address our primary hypothesis, the
sample size is estimated to be 100 participants per group
(200 total). Sample size calculations were performed by
simulating 1000 samples on SAS software with basic dis-
tribution features of our pilot study. The following
assumptions were made:
1. We assume that 28-day mortality will be 30% and
20% in control and EPVent groups, respectively (con-
servative estimate as compared with 38.7% in the
conventional treatment and 16.7% in the EPVent
treatment observed in the phase I study).
2. The distribution of days free from ventilation fol-
lowed the properties of the pilot study and was
assigned in two stages. First, the proportion of
patients with 0 days free from ventilation was assigned
(as 10% in the conventional treatment and 15% in
the EPVent treatment, reﬂecting the higher percent-
age of alive but still ventilated patients at day 28 in
the EPVent group). Second, the remaining values
were assigned normal values with mean equal to 13.0
and 15.0 days in the conventional and EPVent
groups, respectively (SD 6.5 days in both groups).
Statistical methods
Primary analyses
Primary analyses will use the set of all randomised parti-
cipants (intention-to-treat (ITT) sample). We anticipate
compliance to be high, but it is possible that patients in
the EPVent arm may not initiate the EPVent protocol
due to difﬁculty placing the esophageal balloon. In add-
ition, patients who die in the ﬁrst 24 h might be too sick
to gain from the presumed beneﬁt of EPVent-based ven-
tilation. Therefore, a second analysis set, per protocol
(PP sample) will use participants who (A) survived 24 h
from randomisation; (B) underwent the assigned inter-
vention (ie, the control or intervention ventilation proto-
col was initiated and successfully implemented for at
least 24 h) and (C) have data on day 28 assessment avail-
able. The results of analyses using PP will be compared
with results using the full set of all randomised partici-
pants (ITT analyses) to test sensitivity of primary
ﬁndings.
Missing data
We anticipate that the proportion of participants with
missing primary evaluation will be small (<1%). For the
primary analysis, we will assign death to all patients lost
to follow-up prior to the 28 days. Secondary sensitivity
analysis will consider these patients alive and their
Table 4 Oxygenation management table—control group
Step 1 2 3 4 567891 0 1 1 1 2 1 3 1 4 1 5 1 6 1 7
FiO2 0.3 0.3 0.3 0.4 0.4 0.4 0.4 0.4 0.5 0.5 0.6 0.7 0.8 0.8 0.9 1.0 1.0
PEEP 5 8 10 10 12 14 16 18 18 20 20 20 20 22 22 22 24
FiO2, fraction of inspired oxygen; PEEP, positive end-expiratory pressure.
Table 5 Biomarkers of interest
Plasma biomarker Importance in ALI/ARDS development
Surfactant protein-D (SP-D)
11–13 Reflect injury and↑permeability of alveolar epithelium
Receptor for advanced glycation end products (RAGE)
14–16 Reflects endothelial activation and injury
Intercellular adhesion molecule-1 (ICAM-1)
17–20 Reflects endothelial activation and injury
Interleukin-6 (IL-6)
13 21–23 Inflammation
IL-8
13 16 20–23 Inflammation
Plasminogen activator inhibitor-1 (PAI-1)
13 20 24–28 Activation of coagulation and inhibition of fibrinolysis
Von Willebrand factor (VWF)
26 29 30 Reflects endothelial activation and injury
Protein C (PROTC)
13 20 24 28 31 Activation of coagulation and inhibition of fibrinolysis
Tumour necrosis factor receptor (TNFR)
13 32 33 Inflammation
ARDS, acute respiratory distress syndrome.
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available observation.
Interim analyses
An interim analysis is planned at 50% of enrolment. We
do not propose an early stopping rule for efﬁcacy or
futility as this phase II trial is unlikely to result in a
beneﬁt with CIs narrow enough to provide compelling
evidence to change practice. However, the DSMB may
stop the trial for safety at any time. The DSMB opera-
tions (reporting structure, speciﬁc stopping rules, etc)
are outlined in a DSMB charter signed and approved by
all members.
Clinical events, including death, are evaluated for
expectedness based on the patient’s condition and on
possible relationship to trial participation. Events and
classiﬁcations are tabulated and summarised by treat-
ment group. Also, all serious and unexpected adverse
events will be summarised by the treatment group.
Fisher’s exact test will be used to estimate treatment dif-
ferences in the incidence of each speciﬁed adverse
event. No adjustments will be made for multiple hypoth-
esis evaluations of safety end points.
Safety, ethics and dissemination
Adverse outcomes
Safety data including adverse events such as esophageal
injury, loss of airway related to balloon placement,
abnormal air collection, barotrauma, pneumothorax,
unexpected haemodynamic instability and mortality will
be recorded. Adverse events will be deﬁned as ‘unex-
pected’, ‘expected’, graded by severity
(mild-moderate-severe), and classiﬁed as ‘serious’ or
‘non-serious’. As our patient population is by deﬁnition
critically ill, it is expected that patients will have a
number of unrelated adverse health events during the
course of their hospital stay. Therefore, we will limit the
scope of our adverse event monitoring and recording to
the following:
1. Serious adverse events (SAEs) will be deﬁned as:
▸ Death, believed to be related to the study medica-
tion or procedures, or a death that is unexpected
considering the acuity of a patient.
▸ A life-threatening experience believed to be
related to the study medication or procedures.
▸ Persistent or signiﬁcant disability or incapacity
that is of greater frequency or severity than what
would be normally expected in the course of crit-
ical illness.
▸ An event that jeopardises the human subject and
may require medical or surgical treatment to
prevent one of the preceding outcomes and is not
expected in the course of critical illness.
2. Adverse events possibly related to esophageal balloon
placement or mechanical ventilation will be deﬁned
as:
▸ Barotrauma;
▸ Pneumothorax;
▸ Other abnormal air collection (eg, development
of new bronchopleural ﬁstula);
▸ Loss of airway related to device;
▸ Haemodynamic instability.
Role of the DSMB
Safety oversight will be under the direction of an inde-
pendent DSMB. All SAEs will be reported to the site
Institutional Review Board (IRB) and MCC within 24 h
of the research team learning about the event followed
by a more detailed written report to the local IRB. Sites
will inform the MCC of any and all related adverse
events (non-serious) within 14 days of discovery. The
MCC will prepare summaries of all reports and provide
them to the DSMB at least every 6 months. The DSMB
will convene by teleconferencing or in person at 25%,
50% and 75% of enrolment to review adverse events or
earlier if so needed. The NHLBI will be invited to all
DSMB meetings and kept apprised of any safety
concerns.
Ethics approval
Approvals of the protocol and informed consent forms
were obtained from the DSMB and the NHLBI prior to
enrolling the ﬁrst study participant. In addition,
approvals of the protocol and informed consent docu-
ments were required and obtained from the IRB of each
participating institution prior to enrolling study partici-
pants at the respective study site. To ensure that each
participating institution’s informed consent documenta-
tion complied with NHLBI requirements and the code
of federal regulations (CFRs) Title 21 Part 50 Section
Table 6 Assignment of scores for primary outcome
Mortality Days off ventilator Score
Scenario Control EPVent Control versus EPVent Control EPVent
1N o N o > + 1 −1
2N o N o < −1+ 1
3N o N o = 0 0
4 Yes Yes [>, <, =][>, <, =][>, <, =] 0 0
5 No Yes +1 −1
6 Yes No −1+ 1
EPVent, Esophageal Pressure-Guided Ventilation.
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approved by the MCC. Ofﬁcial documentation of all IRB
approvals and all ﬁnalised informed consent forms have
been collected and stored by the MCC.
Considerations for continuation to a phase III clinical trial
The decision to proceed with a phase III trial is formally
outlined as follows:
1. Initiate phase III study: demonstrated efﬁcacy signal
in addition to adequate safety proﬁle.
2. Criteria: primary end point of the trial achieves statis-
tical signiﬁcance.
3. Further development potentially required: weak efﬁ-
cacy signal.
4. Criteria: primary end point did not achieve a priori
level of signiﬁcance but is in the right direction and
there was a general consistency of secondary end
points, indicating propensity for efﬁcacy and no
increased mortality in the treatment arm.
5. Abandon treatment platform: harm (in efﬁcacy or
safety end points).
6. Criteria: study terminated early per recommendation
by DSMB for safety and/or risk/beneﬁt ratio con-
cerns (ie, stop for harm, unacceptable risk proﬁle,
etc).
Ancillary study
At the primary centre, all patients enrolled in the study
will be invited to join an ancillary study with CT
imaging. This substudy will apply established and
accepted CT imaging techniques, as well as serial meas-
urement of non-invasive oscillatory impedance of the
lung, to seek insights into the mechanism of clinical
beneﬁt of the primary trial.
DISCUSSION
We present the study protocol and data analysis plans
for a phase II, multicentre randomised clinical trial that
will assess the impact of mechanical ventilation directed
at maintaining a positive PTP in patients with ARDS.
Speciﬁcally, we have hypothesised that adjusting ventila-
tor pressure to achieve positive PTP values will lead to
improvement in a composite outcome of mortality and
time off the ventilator at 28 days. Secondarily, this investi-
gation will garner important mechanistic data on PTP
and its correlation with other surrogate physiological
measurements, as well as the potential value of using
relevant biomarkers as biochemical surrogate outcome
markers for mortality in ARDS. Finally, the results of this
study will provide essential information on the scientiﬁc
merit and feasibility of a larger, phase III trial testing the
role of PTP to guide ventilation in ARDS.
This trial builds on our previous phase I study by increas-
ing the number of enrolled patients and by increasing the
number of participating centres, thereby making the
results of the current study more generalisable to the adult
acute care hospital population. This strategy will also allow
us to demonstrate feasibility of implementing our esopha-
geal pressure management technique across multiple
centres.
Another notable strength of the current protocol is a
more clinically relevant primary end point as compared
with our previous study. Studies of patients admitted to
the ICU frequently report ventilator-free days as an
outcome. Unfortunately, this measure does not distin-
guish between patients who have died and those who
remained on the ventilator for 28 days. A more clinically
useful outcome measure is one that takes mortality into
account when calculating VFD. Therefore, we propose a
primary hierarchical end point that incorporates death
and VFD at 28 days in such a manner that death consti-
tutes a more serious outcome.
Several important limitations with the planned investi-
gation are worth being noted. The ﬁrst limitation relates
to the learning curve among centres in achieving accur-
ate measurements of esophageal pressure. Several of the
centres involved in the study routinely use esophageal
pressure measurements in clinical practice and are
familiar with the technique. Training is provided for all
sites, but is particularly important for those sites less
familiar with the techniques of esophageal pressure
measurement and interpretation. Training includes both
didactic lectures in basic respiratory physiology (needed
to interpret the physiological waveforms) and hands-on
experience. The MCC developed training materials for
this purpose. Recurrent training and technical assistance
will be available throughout the study. All waveforms will
be reviewed by the PCL as a measure of quality assur-
ance as well as to gauge the effectiveness of our educa-
tional tools.
A second limitation relates to the time frame of inter-
vention. In the proposed study, the experimental inter-
vention will take place until the patient is weaned from
controlled mechanical ventilation or 28 days, after which
the clinicians caring for the patient will dictate care. An
extended intervention period carries a higher data col-
lection burden, an increased potential for missing data
points and a higher difﬁculty of protocol adherence.
However, choosing an extended intervention period
allows for a potentially greater separation in mortality
curves. Additionally, in clinical practice, most patients
are ventilated for less than 28 days. Thus, we anticipate
the actual study intervention period to be shorter than
28 days.
A third and ﬁnal limitation relates to a potential lack
of efﬁcacy. The null hypothesis may prove to be correct
and there is no beneﬁt to the strategy of maintaining a
positive PTP during mechanical ventilation. While disap-
pointing, a ‘negative’ result is an important result. A
negative result would be important in informing the
community of critical care physicians and suggest a shift
of focus to more fruitful therapeutic interventions. A
lack of efﬁcacy in the primary outcome may be offset by
new ﬁndings in the analysis of secondary outcomes,
which could guide future research. In addition, the
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the exploration of mechanistic outcomes should lead to
important insights into the reasons behind the negative
result and generation of important new knowledge.
CONCLUSION
This manuscript describes the study protocol and ana-
lysis plans for the ﬁrst phase II randomised clinical trial
of the use of PTP to guide ventilation in patients with
ARDS. This protocol represents important improve-
ments from our phase I study by increasing the number
of enrolled patients and participating centres, as well as
an improved primary end point. In addition to providing
important information on the safety and efﬁcacy of the
use of esophageal pressure in managing ventilation in
patients with moderate-to-severe ARDS, the results of
this clinical trial will also inform the scientiﬁc commu-
nity regarding the merit and feasibility of a more deﬁni-
tive phase III clinical trial.
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